Trial · NCT02965573
Results by group240
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 240
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | At least 1 TEAE | 10 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | At least 1 TEAE | 10 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | At least 1 treatment-related TEAE | 8 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | At least 1 treatment-related TEAE | 3 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | At least 1 treatment emergent SAE | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | At least 1 treatment emergent SAE | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | Withdrawn from treatment with at least 1 TEAE | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | Withdrawn from treatment with at least 1 TEAE | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | Discontinued study due to at least 1 TEAE | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | Discontinued study due to at least 1 TEAE | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | NCI-CTCAE severity Grade ≥3 | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | NCI-CTCAE severity Grade ≥3 | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | ARGX-113 | Number of Deaths | 0 | Participants | |
| Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) | Placebo | Number of Deaths | 0 | Participants | |
| Mean Change From Baseline in Vital Signs: Blood Pressure | ARGX-113 | Systolic- Day 8 | 3.8 | Standard Deviation 9.12 | millimeters mercury |
| Mean Change From Baseline in Vital Signs: Blood Pressure | Placebo | Systolic- Day 8 | 6.3 | Standard Deviation 10.52 | millimeters mercury |
| Mean Change From Baseline in Vital Signs: Blood Pressure | ARGX-113 | Systolic- Day 15 | 4.5 | Standard Deviation 15.62 | millimeters mercury |
| Mean Change From Baseline in Vital Signs: Blood Pressure | Placebo | Systolic- Day 15 | 2.7 | Standard Deviation 10.97 | millimeters mercury |
| Mean Change From Baseline in Vital Signs: Blood Pressure | ARGX-113 | Systolic- Day 22 | 2.7 | Standard Deviation 9.30 | millimeters mercury |
| Mean Change From Baseline in Vital Signs: Blood Pressure | Placebo | Systolic- Day 22 | 3.0 | Standard Deviation 13.03 | millimeters mercury |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02965573/results